Molecular Imaging for Estrogen Receptor-Positive Breast Cancer

18F-fluoroestradiol (18F-FES) is a Food and Drug Administration-approved radiopharmaceutical used for molecular imaging of the estrogen receptor (ER). When combined with PET, 18F-FES may improve the diagnosis of ER-positive breast cancer in the metastatic setting and provide insights into tumor heterogeneity. In this article, we review data on the use of 18F-FES imaging for treatment selection, staging, imaging lobular breast cancer, and the novel breast specific imaging tool, dedicated breast PET.

Source: Surgical Oncology Clinics of North America - October 1, 2022 Category: Surgery Authors: Kent Goodman, Mary Kathryn Abel, Courtney Lawhn-Heath, Julissa Molina-Vega, Ella F. Jones, Rita A. Mukhtar Source Type: research